Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$17.85 - $40.7 $2.68 Million - $6.11 Million
150,000 Added 27.78%
690,000 $13.4 Million
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $2.86 Million - $7.58 Million
182,763 Added 51.16%
540,000 $18.5 Million
Q1 2022

May 16, 2022

SELL
$20.92 - $39.36 $209,200 - $393,600
-10,000 Reduced 2.72%
357,237 $8.15 Million
Q4 2021

Feb 14, 2022

SELL
$31.94 - $54.82 $3.28 Million - $5.63 Million
-102,763 Reduced 21.86%
367,237 $13.5 Million
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $842,720 - $1.36 Million
18,320 Added 4.06%
470,000 $22.1 Million
Q2 2021

Aug 16, 2021

BUY
$31.92 - $60.25 $14.4 Million - $27.2 Million
451,680 New
451,680 $27.2 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $317M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.